Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERBB2 | P04626 | 12/20 | 0.47 |
| ▸ | EGFR | P00533 | 8/20 | 0.47 |
| ▸ | SRC | P12931 | 3/20 | 0.36 |
| ▸ | BRD4 | O60885 | 2/20 | 0.35 |
| ▸ | IL17A | Q16552 | 1/20 | 0.35 |
| ▸ | KDR | P35968 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29285047 | 0.83 | STS (0.39) | ERBB2EGFR | |
| SCHEMBL3275698 | 0.82 | SRC (0.51) | EGFRSRCBRD4IL17AKDR | |
| SCHEMBL21886695 | 0.82 | EGFR (0.46) | ERBB2EGFRSRCBRD4 | |
| SCHEMBL21886642 | 0.81 | ERBB2 (0.46) | ERBB2EGFRSRC | |
| SCHEMBL21474538 | 0.80 | ERBB2 (0.53) | ERBB2EGFRSRCKDR | |
| SCHEMBL30988726 | 0.80 | ERBB2 (0.53) | ERBB2EGFRSRCKDR | |
| SCHEMBL29609262 | 0.75 | PDE3B (0.50) | SRCBRD4IL17A | |
| SCHEMBL615784 | 0.75 | PDE3B (0.50) | SRCBRD4IL17A | |
| SCHEMBL3282936 | 0.75 | ALDH1A1 (0.41) | EGFRSRCBRD4IL17A | |
| SCHEMBL16747788 | 0.74 | KDR (0.40) | EGFRSRCBRD4IL17AKDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118255772-A | Quinazoline derivatives as antitumor agents | 苏州赞荣医药科技有限公司 | 2024-06-28 | — | — | CN | disclosed |
| US-11713306-B2 | 5-substituted difluoropiperidine compounds with blood-brain barrier penetrable capability | WAYSHINE BIOPHARM HOLDING LIMITED (KY) | 2023-08-01 | — | — | US | disclosed |
| US-11713306-B2 | 5-substituted difluoropiperidine compounds with blood-brain barrier penetrable capability | WAYSHINE BIOPHARM HOLDING LIMITED (KY) | 2023-08-01 | — | — | US | disclosed |
| EP-3778589-B1 | 5-SUBSTITUTED DIFLUOROPIPERIDINE COMPOUND CAPABLE OF PASSING THROUGH BLOOD-BRAIN BARRIER | WEISHANG SHANGHAI BIO PHARMACEUTICAL CO LTD (CN) | 2022-05-11 | — | — | EP | disclosed |
| CN-112654612-A | Quinazoline derivatives as antitumor agents | 苏州赞荣医药科技有限公司 | 2021-04-13 | — | — | CN | disclosed |
| EP-3778589-A1 | 5-SUBSTITUTED DIFLUOROPIPERIDINE COMPOUND CAPABLE OF PASSING THROUGH BLOOD-BRAIN BARRIER | Weishang (Shanghai) Bio-Pharmaceutical Co., Ltd. (CN) | 2021-02-17 | — | — | EP | disclosed |
| US-20210017159-A1 | 5-SUBSTITUTED DIFLUOROPIPERIDINE COMPOUNDS WITH BLOOD-BRAIN BARRIER PENETRABLE CAPABILITY | WEISHANG (SHANGHAI) BIO-PHARMACEUTICAL CO., LTD. (CN) | 2021-01-21 | — | — | US | disclosed |
| WO-2019196622-A1 | 5-SUBSTITUTED DIFLUOROPIPERIDINE COMPOUND CAPABLE OF PASSING THROUGH BLOOD-BRAIN BARRIER | 威尚（上海）生物医药有限公司 | 2019-10-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11713306-B2 | 5-substituted difluoropiperidine compounds with blood-brain barrier penetrable capability | FYN, KDR, FLT1 | ERBB2 7/4885EGFR 11/4885SRC 9/4885 |
| US-20210017159-A1 | 5-SUBSTITUTED DIFLUOROPIPERIDINE COMPOUNDS WITH BLOOD-BRAIN BARRIER PENETRABLE CAPABILITY | FYN, KDR, FLT1 | ERBB2 7/4885EGFR 11/4885SRC 9/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.